在较低血管加压药剂量下启动血管紧张素II治疗血管舒张性休克:ATHOS-3临床试验的探索性事后分析
该研究为ATHOS-3试验的探索性事后分析,纳入321例血管舒张性休克患者,随机接受血管紧张素II或安慰剂(均联合标准血管加压药)。按启动研究药物时的去甲肾上腺素等效剂量(NED)分为低剂量组(≤0.25 µg/kg/min,n=104)和高剂量组(>0.25 µg/kg/min,n=217)。主要终点为低NED亚组中AT II与安慰剂的28天生存差异。结果显示,低NED亚组中AT II组28天死亡风险约为安慰剂组的一半(HR 0.509;95%CI 0.274-0.945,p=0.03),高NED亚组无差异(HR 0.933;95%CI 0.644-1.350,p=0.71)。作者认为这些数据可能为前瞻性试验设计提供信息。
要点
- 低NED亚组(≤0.25 µg/kg/min)中,AT II组28天死亡风险显著低于安慰剂组(HR 0.509;95%CI 0.274-0.945,p=0.03)。
- 高NED亚组(>0.25 µg/kg/min)中,AT II与安慰剂28天生存无差异(HR 0.933;95%CI 0.644-1.350,p=0.71)。
- 低NED亚组中AT II组严重不良事件较安慰剂组少,但差异无统计学意义;高NED亚组两组严重不良事件相当。
- 低NED亚组基线NED中位数两组相似(AT II组0.21 µg/kg/min vs 安慰剂组0.21 µg/kg/min,p=0.45)。
- 高NED亚组基线NED中位数两组相似(AT II组0.47 µg/kg/min vs 安慰剂组0.45 µg/kg/min,p=0.75)。
适用人群与场景
- 血管舒张性休克患者,在标准血管加压药支持下仍存在低血压(平均动脉压55-70 mmHg),且去甲肾上腺素等效剂量(NED)>0.2 µg/kg/min。
- 按研究药物启动时NED分为低剂量组(≤0.25 µg/kg/min,n=104)和高剂量组(>0.25 µg/kg/min,n=217)。
处置流程与药物剂量
- 在标准血管加压药治疗基础上加用血管紧张素II或安慰剂(具体剂量方案未在本文报告)。
研究设计与关键结果
- 研究类型:ATHOS-3试验的探索性事后分析;样本量321例;人群为血管舒张性休克患者;干预为血管紧张素II联合标准血管加压药,对照为安慰剂联合标准血管加压药;主要终点为低NED亚组(≤0.25 µg/kg/min)中AT II与安慰剂的28天生存差异。
- 低NED亚组(n=104):AT II组(n=56)与安慰剂组(n=48)基线NED中位数均为0.21 µg/kg/min(p=0.45);校正疾病严重程度后,AT II组28天死亡风险为安慰剂组的一半(HR 0.509;95%CI 0.274-0.945,p=0.03)。
- 高NED亚组(n=217):AT II组(n=107)基线NED中位数0.47 µg/kg/min vs 安慰剂组(n=110)0.45 µg/kg/min(p=0.75);28天生存无差异(HR 0.933;95%CI 0.644-1.350,p=0.71)。
- 低NED亚组中AT II组严重不良事件较安慰剂组少,但差异无统计学意义;高NED亚组两组严重不良事件相当。
证据类型、等级与局限
- 证据类型:3期随机对照试验(ATHOS-3)的探索性事后分析。
- 局限:原文报告为探索性事后分析;作者指出这些数据可能为前瞻性试验设计提供信息。
对床旁实践的改变
- 作者认为,在较低剂量的其他血管加压药时引入AT II可能有益;这些数据可能为前瞻性试验设计提供信息。
指南或共识出处
- ATHOS-3试验(NCT02338843,2015年1月14日注册)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: High dose vasopressors portend poor outcome in vasodilatory shock. We aimed to evaluate the impact of baseline vasopressor dose on outcomes in patients treated with angiotensin II (AT II).
METHODS: Exploratory post-hoc analysis of the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) trial data. The ATHOS-3 trial randomized 321 patients with vasodilatory shock, who remained hypotensive (mean arterial pressure of 55-70 mmHg) despite receiving standard of care vasopressor support at a norepinephrine-equivalent dose (NED) > 0.2 µg/kg/min, to receive AT II or placebo, both in addition to standard of care vasopressors. Patients were grouped into low (≤ 0.25 µg/kg/min; n = 104) or high (> 0.25 µg/kg/min; n = 217) NED at the time of study drug initiation. The primary outcome was the difference in 28-day survival between the AT II and placebo subgroups in those with a baseline NED ≤ 0.25 µg/kg/min at the time of study drug initiation.
RESULTS: Of 321 patients, the median baseline NED in the low-NED subgroup was similar in the AT II (n = 56) and placebo (n = 48) groups (median of each arm 0.21 µg/kg/min, p = 0.45). In the high-NED subgroup, the median baseline NEDs were also similar (0.47 µg/kg/min AT II group, n = 107 vs. 0.45 µg/kg/min placebo group, n = 110, p = 0.75). After adjusting for severity of illness, those randomized to AT II in the low-NED subgroup were half as likely to die at 28-days compared to placebo (HR 0.509; 95% CI 0.274-0.945, p = 0.03). No differences in 28-day survival between AT II and placebo groups were found in the high-NED subgroup (HR 0.933; 95% CI 0.644-1.350, p = 0.71). Serious adverse events were less frequent in the low-NED AT II subgroup compared to the placebo low-NED subgroup, though differences were not statistically significant, and were comparable in the high-NED subgroups.
CONCLUSIONS: This exploratory post-hoc analysis of phase 3 clinical trial data suggests a potential benefit of AT II introduction at lower doses of other vasopressor agents. These data may inform design of a prospective trial.
TRIAL REGISTRATION: The ATHOS-3 trial was registered in the clinicaltrials.gov repository (no. NCT02338843). Registered 14 January 2015.
参考来源
- Wieruszewski PM, Bellomo R, Busse LW, et al. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care. 2023. PMID: 37147690. doi:10.1186/s13054-023-04446-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。